NVP-BEZ235 inhibits thyroid cancer growth by p53- dependent/independent p21 upregulation

NVP-BEZ235 is a novel dual PI3K/mTOR inhibitor, currently in phase 1/2 clinical trials, exhibiting clinical efficiency in treatment of numerous malignancies including thyroid cancer. Cancer cells harboring mutant p53 was widely reported to be blunt to pharmaceutical therapies. However, whether this...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruan, Banjun, Liu, Wei, Chen, Pu, Cui, Rongrong, Li, Yu, Ji, Meiju, Hou, Peng, Yang, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990918/
https://www.ncbi.nlm.nih.gov/pubmed/32025215
http://dx.doi.org/10.7150/ijbs.37592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990918/
https://www.ncbi.nlm.nih.gov/pubmed/32025215
http://dx.doi.org/10.7150/ijbs.37592

Ejemplares similares